ERAS
Price
$1.45
Change
+$0.03 (+2.11%)
Updated
Jun 3 closing price
Capitalization
409.35M
64 days until earnings call
XNCR
Price
$9.14
Change
+$0.56 (+6.53%)
Updated
Jun 3 closing price
Capitalization
650.5M
56 days until earnings call
Interact to see
Advertisement

ERAS vs XNCR

Header iconERAS vs XNCR Comparison
Open Charts ERAS vs XNCRBanner chart's image
Erasca
Price$1.45
Change+$0.03 (+2.11%)
Volume$2.04M
Capitalization409.35M
Xencor
Price$9.14
Change+$0.56 (+6.53%)
Volume$1.39M
Capitalization650.5M
ERAS vs XNCR Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. XNCR commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and XNCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (ERAS: $1.45 vs. XNCR: $9.14)
Brand notoriety: ERAS and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 123% vs. XNCR: 135%
Market capitalization -- ERAS: $409.35M vs. XNCR: $650.5M
ERAS [@Biotechnology] is valued at $409.35M. XNCR’s [@Biotechnology] market capitalization is $650.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than XNCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 6 TA indicator(s) are bullish while XNCR’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 6 bullish, 4 bearish.
  • XNCR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than XNCR.

Price Growth

ERAS (@Biotechnology) experienced а +33.80% price change this week, while XNCR (@Biotechnology) price change was +17.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.76%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was +0.74%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

XNCR is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+5.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XNCR($651M) has a higher market cap than ERAS($409M). ERAS YTD gains are higher at: -42.430 vs. XNCR (-60.226). ERAS has higher annual earnings (EBITDA): -151.33M vs. XNCR (-161.68M). XNCR has more cash in the bank: 470M vs. ERAS (319M). ERAS has less debt than XNCR: ERAS (52.9M) vs XNCR (67.8M). XNCR has higher revenues than ERAS: XNCR (127M) vs ERAS (0).
ERASXNCRERAS / XNCR
Capitalization409M651M63%
EBITDA-151.33M-161.68M94%
Gain YTD-42.430-60.22670%
P/E RatioN/AN/A-
Revenue0127M-
Total Cash319M470M68%
Total Debt52.9M67.8M78%
FUNDAMENTALS RATINGS
XNCR: Fundamental Ratings
XNCR
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
96
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASXNCR
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 3 days ago
66%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 3 days ago
66%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 14 days ago
88%
Bearish Trend 29 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DIFAX12.18N/A
N/A
MFS Diversified Income A
CMGIX43.39N/A
N/A
BlackRock Mid-Cap Growth Equity Instl
PMIYX10.65N/A
N/A
Putnam Multi-Asset Income Y
LFLTX13.68N/A
N/A
Lord Abbett Focused Large Cap Value R5
JEQSX36.46N/A
N/A
Johnson Equity Income S

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.40%
RVMD - ERAS
57%
Loosely correlated
-0.17%
LRMR - ERAS
56%
Loosely correlated
+9.30%
XNCR - ERAS
54%
Loosely correlated
+6.53%
ATXS - ERAS
53%
Loosely correlated
+3.77%
APGE - ERAS
53%
Loosely correlated
+2.06%
More